Abstract |
Based on its electrophysiologic characteristics, encainide, a new type 1 antiarrhythmic agent, was selected for a therapeutic trial in a case of refractory paroxysmal atrial fibrillation. This approach represents an attempt to manage the pathophysiologic disturbance of atrial fibrillation by selection of a drug that would be expected to have specific effects on the conduction system.
|
Authors | S C Vlay, P R Reid |
Journal | Clinical cardiology
(Clin Cardiol)
Vol. 7
Issue 9
Pg. 498-502
(Sep 1984)
ISSN: 0160-9289 [Print] United States |
PMID | 6442224
(Publication Type: Case Reports, Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Anilides
- Anti-Arrhythmia Agents
- Verapamil
- Encainide
|
Topics |
- Anilides
(therapeutic use)
- Anti-Arrhythmia Agents
(therapeutic use)
- Atrial Fibrillation
(drug therapy, physiopathology)
- Encainide
- Humans
- Male
- Verapamil
(therapeutic use)
|